November #107 : In Stores-and In Store - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Vote '04-Who’s better for people with HIV?

Vote '04-We Have Issues

Vote '04-4 More Years?!?

Vote '04-Who Ya For?

Vote '04-Full-Frontal Election

Vote '04-Hot Seats


Back to School

When Life Hands You Lemons...

One Hot Tomato

Microbicide Update

Sayonara, Suckers

Waiting to Exhale

Pos & Neg

Fit to Print

Website of the Month


Meet Your Host


In Stores-and In Store

Brush With Nausea

Rebel With a Cause

A Woman’s Guide to Living With HIV Infection

Those Other Pills

Marijuana Mama

Found a cure

Founder's Letter


Senior Class


Inside Story

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

November 2004

In Stores-and In Store

by Tim Horn

This year, drug companies have shoehorned daily fistfuls of meds into fewer pills and doses. Next year. they'll focus on resistance-fighting compounds

If only the names were simple Truvada and Epzicom, a duo of two-in-one combo nukes, have hit pharmacy shelves, challenging Combivir (3TC/AZT). Truvada, Gilead Sciences’ fixed-dose combination (FDC) capsule, mixes 300 mg Viread (tenofovir) with 200 mg Emtriva (FTC). GlaxoSmithKline’s Epzicom combines 600 mg Ziagen (abacavir) and 300 mg Epivir (3TC). Both FDCs conveniently require only one pill daily, taken typically with a non-nuke or protease inhibitor (PI). “The only thing better would be to get a full regimen into a fixed-dose combination,” says Tom Gegeny of the AIDS Treatment Activists Coalition.

Hold that thought Gilead, Bristol-Myers Squibb and Merck say they’re teaming up on a once-daily Sustiva (efavirenz)/Viread/Emtriva tablet to meet adherence demands in nations rich and poor. (Merck markets efavirenz in some parts of the world.)

Not so simple Abbott filed for FDA approval to study Kaletra (lopinavir/ritonavir) as a once-daily—but only for new-to-HAART HIVers (once-a-day doses may not keep drug levels consistent enough to overcome resistant HIV in others). Another party pooper: In tests, the once-a-day sent more people running for the loo than its twice-daily ancestor.

Alive in 2005 Tipranavir, Boehringer Ingelheim’s PI, is likely to be the only new HAART med approved next year—along with its doesn’t-play-well-with-other-PIs, needs-a-big-boost limitations (see “Trouble for Tipranavir,” POZ, September 2004).

Coming Attraction Reverset, from HIV newcomers Pharmasset and Incyte, may help HIVers with multi-nuke resistance. The new nuke trounces many resistant HIV strains but can cause—and is less active against—the dreaded K65R mutation (think Viread resistance). In a recent study, eight much-treated HIVers added once-daily Reverset to a failing regimen. Ten days later, four had undetectable viral loads; 20 days after the drug was stopped, viral loads were still below their pre-Reverset levels. But “we need long-term data,” Gegeny says. “Many promising candidates have fallen by the wayside when data from larger studies show unexpected and unsafe results.” Phase II studies are underway, with larger Phase III studies expected next summer.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.